<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67319">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02148939</url>
  </required_header>
  <id_info>
    <org_study_id>Stroke</org_study_id>
    <nct_id>NCT02148939</nct_id>
  </id_info>
  <brief_title>Antiplatelet Effects in Stroke-Patients</brief_title>
  <official_title>Dipyrone Nullifies Aspirin Antiplatelet Effects in Stroke-Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many patients suffer from acute and chronic pain. The incidence of chronic pain correlates
      with increased age. Most of patients rely on analgesic medication to control the pain.
      Dipyrone is an extensively used drug in Western and Eastern Europe as well as Central and
      South America, largely due to its favorable analgesic and antipyretic effects in conjunction
      with a low incidence of gastrointestinal complications when compared to other non-steroidal
      anti-inflammatory drugs (NSAIDs).

      Aspirin is the backbone of antiplatelet therapy in patients after ischemic stroke. However,
      it is known that there are substantial inter-individual response variabilities to
      antiplatelet medication. Furthermore, patients with impaired response to aspirin have a
      significant higher risk of recurrent cerebro-vascular events. The investigators have
      recently shown that co-medication with aspirin and dipyrone in patients with coronary artery
      disease lead to insufficient antiplatelet effects of aspirin.

      The incidence of chronic pain is very high in patients with ischemic stroke. Therefore, in
      this study the investigators aim to examine, if co-medication of aspirin and dipyrone
      interaction also occurs in patients after ischemic stroke.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Laboratory response to aspirin therapy in metamizole co-medicated Stroke patients</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACCE Events during hospital stay</measure>
    <time_frame>participants are followed until discharge up to 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ischemic Stroke</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with ischemic stroke
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Patients with ischemic stroke and ASS-medication (80-320 mg/day) with/without
             analgesic comedication

        Exclusion Criteria:

          -  Reanimation

          -  cardiogenic shock
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amin Polzin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Kariologie, Pneumologie und Angiologie, Universtiätsklinikum Düsseldorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias Zeus, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinik für Kariologie, Pneumologie und Angiologie, Universtiätsklinikum Düsseldorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amin Polzin, MD</last_name>
    <phone>+49 2118118800</phone>
    <email>amin.polzin@med.uni-duesseldorf.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Cardiology, Pulmonary Disease and Vascular Medicine</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amin Polzin, MD</last_name>
      <phone>+49 2118118800</phone>
      <email>amin.polzin@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Amin Polzin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tobias Zeus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uniklinik-duesseldorf.de/kardiologie</url>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>May 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik für Kardiologie, Pneumologie und Angiologie</investigator_full_name>
    <investigator_title>Division of Cardiology, Pulmonary Diseases, Vascular Medicine</investigator_title>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>Antiplatelet Effects</keyword>
  <keyword>aspirin</keyword>
  <keyword>metamizole</keyword>
  <keyword>dipyrone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
